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Abstract
Membrane-associated mucins (MAMs) expressed on the ocular surface epithelium form a dense 
glycocalyx, which is hypothesized to protect the cornea and conjunctiva from external insult. In 
this study, the hypothesis that the MAMs MUC1 and MUC16, expressed on the apical surface of 
the corneal epithelium, suppress Toll-like receptor (TLR)-mediated innate immune responses was 
tested. Using an in vitro model of corneal epithelial cells that are cultured to express MAMs, we 
show that reduced expression of either MUC1 or MUC16 correlates with increased message and 
secreted protein levels of the proinflammatory cytokines IL-6, IL-8, and TNF-α following 
exposure of cells to the TLR2 and TLR5 agonists, heat killed Listeria monocytogenes and 
flagellin, respectively. Since mice express MUC1 (but not MUC16) in the corneal epithelium, a 
Muc1-/- mouse model was used to extend in vitro findings. Indeed, IL-6 and TNF-α message 
levels were increased in the corneal epithelium of Muc1-/- mice, in comparison to wild type mice, 
following exposure of enucleated eyes to the TLR2 and TLR5 agonists. Our results suggest that 
the MAMs MUC1 and MUC16 contribute to the maintenance of immune homeostasis at the 
ocular surface by limiting TLR-mediated innate immune responses.
Introduction
The ocular surface epithelium comes in frequent contact with a variety of microorganisms, 
some of which can be pathogenic. However, multiple layers of protection, which include 
components of the mucosal barrier, ensure that the ocular surface epithelium is protected 
from pathogens.
Intrinsic to the mucosal barrier of all wet-surfaced epithelia of the body are a family of 
heavily O-glycosylated proteins known as mucins, which exist in secreted and membrane-
associated forms. Secreted mucins are synthesized by goblet cells and contain cysteine-rich 
domains at their N- and C-termini to facilitate multimerization.1 Membrane-associated 
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mucins (MAMs) possess a hydrophobic transmembrane domain by which they are anchored 
to the apical cell membrane.2 Secreted mucins, which form the bulk of mucous, remain in 
constant motion over epithelial surfaces and trap debris, while MAMs form a continuous 
glycocalyx on the apical side of epithelia and constitute a protective barrier. To date, nearly 
ten different MAMs have been identified. These include MUCs 1, 3A/3B, 4, 12, 13, 15, 16, 
17, 20, and 21 (mucins in humans and mice are abbreviated as MUC and Muc, 
respectively).3, 4 The cytoplasmic tail (CT) of MUC1 is known to participate in signal 
transduction cascades.3, 5 While MUC1 is ubiquitously expressed across all mucosal 
epithelia, all other MAMs exhibit variable expression and distribution patterns. The MAM 
repertoire of the ocular surface epithelium consists primarily of MUCs 1, 4, and 16.6 On the 
ocular surface, MUCs 1 and 16 are expressed on the corneal and conjunctival epithelia, 
while MUC4 is expressed on the conjunctival epithelium.6, 7 Multiple lines of investigation 
have suggested that MUC16 is the major contributor of barrier function on the ocular 
surface.8, 9 Recent work using an in vitro corneal epithelial cell culture system indicates that 
MUC16, but not MUC1, contributes to epithelial barrier function as assessed by dye 
penetrence and bacterial adhesion/invasion assays and by measurements of transepithelial 
resistance.9 As of yet, biological functions for MUC1 on the ocular surface epithelium have 
not been defined.
The innate immune system of the ocular surface, principal components of which include 
Toll-like receptors (TLRs), also plays a crucial role in the early response against pathogens. 
To date, 10 functional TLRs have been identified in humans and 12 in mice.10 These 
receptors sense pathogen-associated molecular patterns (PAMPs) intrinsic to 
microorganisms. Ligation of PAMPs to TLRs triggers signaling pathways, which activate 
the transcription factors nuclear factor-κB (NF-κB) and interferon regulatory factor-3 
(IRF3). These factors then induce the expression of proinflammatory cytokines and 
antimicrobial peptides to neutralize invading pathogens. Several studies have documented 
the role of TLRs at the ocular surface in protection against pathogens.11-17
Although TLR-mediated immune responses against pathogens are protective, an 
uncontrolled response can lead to the unnecessary production of proinflammatory cytokines 
and cause bystander tissue damage.18, 19 Thus, tight control of such responses is as crucial 
as clearing of invading pathogens. Recently, MUC1 and MUC13 have been shown to 
modulate TLR-mediated inflammatory processes in the airway and gastric epithelia.20-23 
The earliest evidence suggesting an anti-inflammatory role for MUC1 came from 
experiments involving lung infection of Muc1-/- mice by P. aeruginosa.24 Muc1-/- mice 
showed decreased lung colonization by P. aeruginosa, increased leukocytic recruitment, and 
elevated IL-8 and TNF-α levels in the bronchoalveolar lavage fluid when compared to their 
wild type littermates.24 Further studies showed that 1) MUC1 suppresses NF-κB activation 
in response to TLR 2, 3, 4, 7, and 9 agonists, thereby suggesting that MUC1 may be a 
universal regulator of TLR signaling,20 2) MUC1 deletion promotes dendritic cell response 
to TLR4 and TLR5 signaling pathways25 and 3) the CT of MUC1 regulates TLR3 and 
TLR5 signaling by associating with these TLRs and inhibiting recruitment of TRIF and 
MyD88 to these receptors.26, 27 Intriguingly, unlike MUC1, MUC13 was found to be 
proinflammatory in the intestinal epithelium.21 Given these opposing immunomodulatory 
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roles and considering that different wet-surfaced epithelia of the body express a variable 
repertoire of MAMs, it is important to understand how specific MAMs regulate 
inflammatory processes across epithelial surfaces. In regard to the ocular surface, no 
information is available about the potential of MAMs to regulate inflammatory responses. 
Moreover, an immunomodulatory function for MUC16 has not been reported. Here, we 
investigate the roles of MUC1 and MUC16 in modulating TLR-mediated innate immune 
responses at the corneal epithelium and report that each MAM suppresses TLR-induced 
expression of the proinflammatory cytokines IL-6, IL-8, and TNF-α.
Materials and Methods
Cell lines and culture methods
A telomerase-transformed HCLE cell line for which mucin gene expression has been well-
characterized was used as an in vitro model.8, 28, 29 The non-transfected HCLE cells 
(HCLE-NT) were cultured and grown to confluence in keratinocyte serum-free medium (K-
SFM) (Invitrogen) containing 25 μg/mL bovine pituitary extract and 0.2 ng/mL epidermal 
growth factor (EGF). Cells were then switched to Dulbecco's Modified Eagle Medium: 
Nutrient Mixture F-12 (DMEM/F12) (Cellgro) supplemented with 10% calf serum and 10 
ng/mL EGF for 7 days to promote differentiation and optimal MAM production.28 Methods 
for generating the HCLE-scrMUC1 and HCLE-scrMUC16 (scramble-transfected HCLE 
cells used as controls), and HCLE-shMUC1 and HCLE-shMUC16 (HCLE cells in which 
MUC1 and MUC16 were stably knocked down) have been described previously.8, 9 The 
HCLE-scrMUC1/HCLE-shMUC1 and HCLE-scrMUC16/HCLE-shMUC16 cells were 
grown and maintained in medium containing blasticidin (5 μg/mL) and puromycin (2.5 μg/
mL), respectively.
Monocytic THP-1 cells were grown to a density of 1 × 106 cells/mL in RPMI 1640 medium 
supplemented with 10% fetal bovine serum, penicillin and streptomycin, and 10 mM L-
glutamine. Differentiation of THP-1 cells was achieved by treating cells with 100 nM 
phorbol 12-myristate 13-acetate (PMA) for 3 days.
Mouse models
Eight to twelve week old, male wild type and Muc1-/- mice, both on a C57BL/6 genetic 
background, were used in in vivo and ex vivo studies. These mice were obtained from the 
laboratory of Dr. Sandra Gendler (Mayo Clinic, Scottsdale, Arizona). Details regarding 
generation of the Muc1-/- mice have been described previously.30 All animal protocols were 
approved by the Schepens Institutional Animal Care and Use Committee (IACUC). 
Muc16-/-mice were not used in this study, since mice do not express Muc16 in the corneal 
epithelium.31
TLR2 and TLR5 agonist exposure in vitro and ex vivo
Agonists to TLR2 – a heat-killed preparation of Listeria monocytogenes (HKLM), and 
TLR5 – flagellin from Salmonella typhimurium, were purchased from InvivoGen. These 
agonists were used at working concentrations recommended by the manufacturer (HKLM - 
108 cells/mL, flagellin - 250 ng/mL). Twenty four hours prior to agonist exposure, stratified 
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HCLE-NT, HCLE-scrMUC1, HCLE-shMUC1, HCLE-scrMUC16, and HCLE-shMUC16 
cells were switched to antibiotic- and EGF-free K-SFM. Cells were then exposed to the 
agonists that were pre-diluted in antibiotic- and EGF-free K-SFM for either 4 h (RNA 
analyses) or 12 h (protein analysis). In ex vivo experiments, eyes of WT and Muc1-/- mice 
were enucleated and independently incubated in antibiotic- and EGF-free K-SFM containing 
a cocktail of the TLR2 and TLR5 agonists at working concentrations described above. 
Following a 4 h exposure to the agonists, the corneal epithelium was carefully debrided 
using a blade attached to a micro blade holder. The debrided epithelium from four eyes of 
each strain was pooled to constitute one sample (total n=3 for WT and n=6 for Muc1-/-, each 
n=4 eyes). Pooled samples were collected in RNA lysis buffer (Qiagen) and stored at -80°C 
until further use.
RNA extraction and quantitative RT-PCR analyses
Total RNA from stratified HCLE-NT, HCLE-scrMUC1, HCLE-shMUC1, HCLE-
scrMUC16, HCLE-shMUC16, and native corneal epithelial cells was extracted using Trizol 
reagent (Life Technologies). Using the iScript cDNA synthesis kit (Bio-Rad), 2 μg of total 
RNA was reverse-transcribed following manufacturer guidelines. For amplifying TLRs, 
cDNA corresponding to the different HCLE cell lines and native corneal epithelial cells was 
used as template in PCRs along with TLR-specific primers that were purchased from 
InvivoGen (Human TLR RT-primers). The positive control used in PCRs was dsDNA from 
monocytic THP-1 cells (InvivoGen). Amplified products were resolved on 1.2% agarose 
gels containing ethidium bromide. Quantitative RT-PCR (qRT-PCR) to measure transcript 
levels of IL-6, IL-8, TNF-α, TLR 2, and TLR5 was performed on an Eppendorf 
Mastercycler ep gradient S platform using TaqMan chemistry and pre-validated primers 
from Life Technologies [IL-6 (Hs00985639_m1), IL-8 (Hs00174103_m1), TNF-α 
(Hs01113624_g1), TLR2 (Hs01872448_s1), TLR5 (Hs01920773_s1), and GAPDH 
(4333764F)]. Data were normalized to the endogenous control, GAPDH, and expressed 
relative to HCLE-NT cells.
RNA from the debrided corneal epithelium of WT and Muc1-/- mice was isolated using the 
RNeasy Micro kit (Qiagen). cDNA synthesis and qRT-PCR analyses to measure transcript 
levels of IL-6 and TNF-α were performed as described above. Pre-validated primers 
purchased from Life Technologies were: IL-6 (Mm00446190_m1), TNF-α 
(Mm00443258_m1), Sprr2h (Mm00488435_s1), Tgm1 (Mm00498375_m1), Muc1 
(Mm00449604_m1), Muc4 (Mm00466886_m1), and GAPDH (Mm99999915_g1). Data 
were normalized to the endogenous control, GAPDH, and expressed relative to WT mice.
Luminex assays for measuring secreted cytokines
IL-6, IL-8, and TNF-α secreted into the culture medium by HCLE-NT, HCLE-scrMUC1, 
HCLE-shMUC1, HCLE-scrMUC16, and HCLE-shMUC16 cells were detected and 
quantified using the Luminex Performance Assay (R&D Systems) following manufacturer 
guidelines. Cells were exposed to the TLR2 and TLR5 agonists for 12 h. For quantifying 
IL-8, 1/20th volume of the cell culture supernatants was used in the assay and for IL-6 and 
TNF-α measurements, 1/2 volume of the culture supernatants was concentrated using a 10 
kDa cutoff concentrator (Millipore). The concentration step was performed to ensure that 
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IL-6 and TNF-α levels were within range of the standard curve. Samples were analyzed 
using a Bio-Rad Bio-Plex analyzer powered by Luminex 100 × MAP technology (Luminex 
Corporation). Resulting fluorescent intensities were used to calculate the concentrations of 
IL-6, IL-8, and TNF-α from a standard curve.
Immunohistochemistry of TLR2 and TLR5
Fresh, non-cultured, human corneal epithelial sheets, removed by epikeratome for corrective 
refractive surgery and frozen in optimal cutting temperature medium within 1 h post 
surgery, were processed for immunohistochemistry. For immunolocalization of TLR2 and 
TLR5, 6 μm cryostat sections were incubated with either rabbit polyclonal anti-TLR2 IgG 
(H175)32, 33 primary antibody (1:50 dilution; Santa Cruz Biotechnology) overnight at 4°C in 
a moist chamber or mouse monoclonal anti-TLR5 IgG (19D759.2)34, 35 primary antibody 
(1:100 dilution; Abcam) for 1 h at room temperature, followed by either FITC-labeled 
donkey anti-rabbit or anti-mouse IgG as the secondary antibody (1:100 dilution; Jackson 
ImmunoResearch) for 1 hour at room temperature. After final washing with PBS, slides 
were mounted in Vectashield medium containing 4′,6-diamidino-2-phenylindole (DAPI). 
Stained sections were viewed under a Zeiss Photoscope III fluorescence microscope. 
Specificities of the polyclonal anti-TLR2 and monoclonal anti-TLR5 antibodies were 
determined by immunoblotting using clarified cell extracts derived from undifferentiated 
and differentiated THP-1 cells,36, 37 human umbilical vein endothelial cells (HUVECs),38, 39 
and HCLE-NT cells (Supplementary Figure S2).
Cell surface biotinylation and immunoblotting
Surface biotinylation of HCLE-NT, HCLE-scrMUC1, HCLE-shMUC1, HCLE-scrMUC16, 
and HCLE-shMUC16 cells was performed using the Pierce Pinpoint Cell Surface Protein 
Isolation Kit (ThermoScientific).29, 40, 41 Biotinylated proteins were separated on 12% SDS-
polyacrylamide gels, electroblotted onto nitrocellulose membranes, and analyzed by 
immunoblotting. Primary antibodies used were rabbit monoclonal anti-TLR2 IgG 
(EPNCIR133, 1:2000 dilution, Abcam), rabbit monoclonal anti-TLR5 IgG (EPR10373, 
1:2000 dilution, Abcam), and rabbit polyclonal anti-GAPDH IgG (FL-375, 1:20,000 
dilution, Santa Cruz Biotech), while the secondary antibody used was HRP-conjugated goat 
anti-rabbit IgG (Santa Cruz Biotechnology). Blots were developed using the SuperSignal 
West Femto Maximum Sensitivity Substrate (Thermo Scientific). Clarified lysates obtained 
from undifferentiated THP-1 cells were used as a positive control for detecting TLR2 and 
TLR5 by immunoblotting.
Statistical analyses
For experiments with cell lines, statistical analyses were performed initially using the One-
Way Anova test to determine overall significance. For internal comparisons, unpaired t tests 
were performed with the Bonferroni correction. When applying the Bonferroni correction, 
p<0.05/2 or 0.025 (because of two comparisons) was used as the cutoff for significance. For 
experiments where WT and Muc1-/- mice were being compared, unpaired t-tests with or 
without the Welch correction was used. The Welch correction was used when the difference 
between two standard deviations was significant. Statistical analyses were performed using 
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the GraphPad Instat 3 program for Macintosh, version 3.1a. Individual p values are indicated 
in the figures.
Results
Differentiated corneal epithelial cells express TLRs 2, 5, 6, and 10
Several laboratories have reported the expression of multiple TLRs by the ocular surface 
that respond to a broad range of PAMPs.11, 14, 42, 43 Studies have also reported contrasting 
views about the expression, distribution, and function of TLRs in the corneal epithelium.18 
Many studies investigating TLR signaling mechanisms at the ocular surface have employed 
monolayer cell cultures that are non-stratified and undifferentiated, where the expression of 
MAMs, especially that of MUC16, does not occur.28 Thus, the effect of MAMs in 
modulating TLR signaling may have been underappreciated.
As a model system in this study, cultured HCLE cells that 1) have been stratified and 
allowed to differentiate for optimal MAM expression and 2) mimic several characteristics of 
the native corneal epithelium upon stratification were used.28 As a first step, the spectrum of 
TLRs expressed by differentiated HCLE cells was determined. By performing RT-PCR 
analyses, HCLE-NT cells were found to express TLRs 2, 5, 6, and 10 (Figure 1). A very 
faint expression of TLR4 was also observed. Importantly, an identical TLR expression 
profile was observed when cDNA derived from fresh human corneal epithelium, removed at 
the time of surgery, was used as template (Figure 1). HCLE-scrMUC1, HCLE-shMUC1, 
HCLE-scrMUC16, and HCLE-shMUC16 were also found to mimic the TLR expression 
profile of HCLE-NT cells (data not shown). Since TLR2 and TLR5 transcripts were found 
to be highly expressed in HCLE cells (Figure 1), agonists specific to these receptors were 
chosen for subsequent experiments. The reason for not choosing agonists to TLR6 and 
TLR10 was because these receptors are functional only upon association with TLR2 and 
neither ligand specificity nor function of TLR10 has been defined.44, 45
TLR2 and TLR5 are expressed by apical and subapical corneal epithelial cells
Three independent studies have reported that TLR5 is expressed by basal and wing cells of 
the corneal epithelium,15, 34, 42 while another study by Li et al46 demonstrated that the 
distribution of this receptor is relatively uniform across the entire human corneal epithelium. 
To clarify, the distribution of TLR5 and of TLR2 in the native human corneal epithelium 
and in differentiated HCLE-NT cells was examined. By immunohistochemical staining of 
cryostat sections of freshly isolated, non-cultured, human corneal epithelial sheets removed 
during refractive surgery, both apical and subapical binding of TLR2- and TLR5- specific 
antibodies was observed (Figure 2A, B). Using a second in vitro method, where surface 
proteins of HCLE-NT cells were biotin-labeled, recovered, and analyzed by 
immunoblotting, TLR2 and TLR5 were detected on the apical surface of stratified HCLE 
cell cultures (Figure 2C, D).
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Expression of IL-6, IL-8, and TNF-α is elevated in HCLE-shMUC1 and HCLE-shMUC16 cells 
following stimulation by TLR2 and TLR5 agonists
To test the hypothesis that the MAMs MUC1 and MUC16 suppress TLR-mediated innate 
immune responses, the responsiveness of differentiated MUC1- and MUC16-knockdown 
HCLE cells to agonists specific to TLR2 and TLR5 was investigated. As outcomes of TLR2 
and TLR5 signaling, the levels of the proinflammatory cytokines IL-6, IL-8, and TNF-α in 
the different cell lines was measured by qRT-PCR. Following exposure of HCLE-NT, 
HCLE-scrMUC1, HCLE-shMUC1, HCLE-scrMUC16, and HCLE-shMUC16 to the 
agonists for 4 h, the message levels of IL-6, IL-8, and TNF-α were several fold higher 
(ranging from 2-fold to 6-fold) in HCLE-shMUC1 and HCLE-shMUC16 cells in 
comparison to the controls (Figure 3A, B). Under conditions where HCLE cells were not 
exposed to any agonist, the message levels of IL-6, IL-8, and TNF-α remained comparable 
among the different cell lines (Supplementary Figure S1) indicating that these cytokines are 
not constitutively overexpressed in the knockdown cells. Also, the levels of IL-6, IL-8, and 
TNF-α secreted into the culture medium by the different cells were measured following a 12 
h agonist exposure. HCLE-shMUC1 and HCLE-shMUC16 cells were found to secrete 
significantly higher levels of IL-6, IL-8, and TNF-α in comparison to control cells (Figure 
3C, D).
TLR2 and TLR5 mRNA/protein expression and surface distribution is not increased in 
MUC1- and MUC16-knockdown cells
The elevated expression of IL-6, IL-8, and TNF-α observed in HCLE-shMUC1 and HCLE-
shMUC16 cells following agonist exposure could be a result of increased TLR2 and TLR5 
expression in these cells. To investigate if this was the case, mRNA and protein levels of 
TLR2 and TLR5 were compared in the different cell lines. qRT-PCR and immunblot 
analyses indicated that the expression of TLR2 and TLR5 is not increased in either HCLE-
shMUC1 or HCLE-shMUC16 cells in comparison to HCLE-NT, HCLE-scrMUC1, and 
HCLE-scrMUC16 cells (Figure 4A, B). Although TLR2 and TLR5 were found to be 
uniformly expressed by the different cell lines, perhaps the surface distribution of these 
receptors may be increased in HCLE-shMUC1 and HCLE-shMUC16 cells, which could also 
explain the elevated expression of IL-6, IL-8, and TNF-α in these cells following agonist 
exposure. To test this possibility, cell surface biotinylation experiments were performed. 
Results showed that the surface distribution of TLRs 2 and 5 remained unaltered between 
the different cell lines (Figure 4C), indicating that the increased expression of IL-6, IL-8, 
and TNF-α observed in the knockdown cells is more likely due to lack of MUC1 or 
MUC16.
IL-6 and TNF-α transcripts are elevated in the corneal epithelium of Muc1-/- mice following 
exposure to the TLR2 and TLR5 agonists
To extend the in vitro observations, ex vivo experiments using eyes derived from 
Muc1-/-mice were performed. If MUC1 suppresses TLR signaling at the ocular surface, as 
seen in HCLE-shMUC1 cells, then the corneal epithelium of Muc1-/- mice should exhibit a 
heightened TLR response following agonist challenge. Indeed, exposure of the enucleated 
eyes derived from Muc1-/- mice to a cocktail of the TLR2 and TLR5 agonists for 4 h 
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resulted in increased message levels of IL-6 and TNF-α in the corneal epithelium as 
compared to the WT condition (Figure 5).
To determine if Muc1-/- mice have an ocular surface phenotype and/or exhibit signs of 
ocular inflammation, fluorescein staining of the ocular surface to assess epithelial defects 
and tear volume measurements was performed. No significant differences between WT and 
Muc1-/- mice were noted (Supplementary Figure S3A, B). Furthermore, expression of 
Sprr2h and Tgm1 (markers of epithelial stress and keratinization, respectively)47 in the 
corneal epithelium did not differ significantly between WT and Muc1-/- mice 
(Supplementary Figure S4). Message levels of Muc4, another MAM expressed by the 
corneal epithelium of mice,48 were also found to be comparable (Supplementary Figure S4), 
suggesting that Muc4 is not upregulated in response to loss of Muc1 in the knockout mice. 
TNF-α (indicative of inflammation) message levels were found to be significantly lower in 
the corneal epithelium of Muc1-/- mice in comparison to WT mice (Supplementary Figure 
S4). Immunohistochemical analyses for determining the presence of inflammatory cells in 
the ocular surface tissue using the pan-leukocyte marker CD45 revealed that the number of 
CD45-positive cells per 1 mm linear length of basal lamina in the corneal epithelium (WT: 
0.1 ± 0.1, Muc1-/-: 0) and corneal stroma (WT: 0.9 ± 0.3, Muc1-/-: 0.4 ± 0.1) were similar 
between WT and Muc1-/- mice. Taken together, these data suggest that C57BL/6 Muc1-/- 
mice do not display an ocular surface phenotype or signs of ocular inflammation, a finding 
that is consistent with the study published by Danjo et al.48
Discussion
This study demonstrates that the MAMs MUC16 and MUC1 each modulate inflammatory 
responses at the corneal epithelium by limiting TLR2- and TLR5-induced expression of the 
pro-inflammatory cytokines IL-6, IL-8, and TNF-α (Figure 6). Although the barrier 
properties of MUC16 have been previously reported,8, 9 this study is the first to assign an 
immunomodulatory role for MUC16. A similar function for MUC1 at the corneal epithelium 
is also described.
The immunomodulatory function of MUC16 may be explained, in part, by the barrier 
function of the glycoprotein. Studies have shown that at the corneal epithelium, 1) MUC16 
is anti-adhesive and prevents colonization of the bacterium Staphylococcus aureus,8, 9 2) 
glycosylation of the MAM and its binding to galectin-3 is crucial for the maintenance of 
mucosal barrier function,49 and 3) knockdown of MUC16 in corneal epithelial cells results 
in reduced transepithelial resistance and disruption of tight junctions.9 Alternatively, 
immunosuppression may also be mediated by the CT of MUC16 through direct association 
with TLRs and/or inhibition of downstream signaling pathways. The CT of MUC16, which 
contains potential serine/threonine/tyrosine phosphorylation sites, was recently found to 
interact with the Src family of kinases (c-Srk and c-Yes),50 which are proteins involved in 
TLR signaling.51 Perhaps such interactions limit the participation of Srk in TLR signaling. 
Another possibility is that MUC16-CT, upon phosphorylation, may directly modulate NF-
κB activity and expression of proinflammatory cytokines.
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The finding that MUC1 suppresses TLR responses at the corneal epithelium is noteworthy 
since the protein's function at the ocular surface has remained elusive thus far. Previously, 
Kardon et al.52 reported that C57BL/6 × SVJ129 Muc1-/- mice developed spontaneous 
conjunctivitis and blepharitis; however, a subsequent study by Danjo et al.,48 showed no 
increased susceptibility of C57BL/6 Muc1-/- mice to infection by Pseudomonas aeruginosa. 
This discrepancy may be due to strain variation, and it is possible that C57BL/6 Muc1-/- 
mice are more resistant to infections, as noted by Kardon et al.52 In this study, at steady 
state, C57BL/6 Muc1-/- mice did not exhibit an ocular surface phenotype or signs of 
inflammation (supplementary data), which is consistent with the findings of Danjo et al.48 
Although MUC1 is a critical component of the mucosal barrier in the gastric 
epithelium,53, 54 loss of MUC1 in corneal epithelial cells correlates with increased barrier 
function.9 Thus, rather than serving as a barrier at the corneal epithelium, MUC1 may exert 
its immunosuppressive function via other mechanisms. Kato et al26 demonstrated that the 
EGF receptor kinase phosphorylates a tyrosine residue in the CT of MUC1, which increases 
its association with TLR5 and blocks MyD88 recruitment to the receptor. This association is 
found to inhibit downstream signal transduction.26 More recently, Sheng et al21 reported 
that MUC1 inhibits inflammatory responses of gastric epithelial cells to TNF-α and to TLR/
NOD1 ligands by suppressing NF-κB activity. Based on these reports, the mechanism of 
MUC1-mediated suppression of TLR responses at the corneal epithelium needs to be further 
evaluated.
The in vitro data that loss of either MUC1 or MUC16 leads to increased TLR responses is a 
conundrum, since the knockdown cells express normal levels of one of these MAMs.9 
However, this is not entirely surprising since, in primary human bronchial epithelial cells, 
where both MUC1 and MUC16 are expressed,55 knockdown of MUC1 alone results in 
enhanced flagellin-induced IL-8 synthesis.24 Perhaps, when expressed together, the CTs of 
both MUC1 and MUC16 interact with a common protein that is involved in TLR signaling 
and when expression of either MAM is reduced/lost, dissociation of this protein triggers an 
elevated TLR response. One such protein may be c-Src as it has been shown to bind to both 
MUC1 and MUC16.50, 56 Since MUC16 does not contain an EGF-like domain in its 
transmembrane domain,57 the possibility of EGF receptor being a common interaction 
partner for both MUC1 and MUC16 can be ruled out.
Previous observations that TLRs 2 and 5 are expressed within the internal layers of the 
corneal epithelium led to the hypothesis that activation of these receptors occurs only upon 
compromise of the epithelial barrier.15, 16, 34, 42 In this study, TLRs 2 and 5 were found to 
be expressed by apical and subapical cells of the corneal epithelium. Based on this 
observation and the finding that reduced expression of MAMs on the apical surface of 
corneal epithelial cells leads to increased TLR-induced expression of proinflammatory 
cytokines, it is proposed that both MUC1 and MUC16 play a role in keeping TLR responses 
in check. The activation state of NF-κB was not assayed in this study. Since all TLR 
signaling pathways, MyD88- or TRIF-dependent, converge on NF-κB and ultimately lead to 
the synthesis of several downstream cytokines including IL-6, IL-8, and TNF-α, the 
expression of these cytokines was assayed as an outcome of TLR signaling.
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In conclusion, findings reported herein suggest a role for both MUC1 and MUC16 in 
preventing unnecessary TLR activation and signaling, and maintenance of immune 
homeostasis at the ocular surface. Future studies will investigate the molecular bases of 
immunosuppression by MUC1 and MUC16 at the ocular surface.
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Figure 1. Expression of TLRs by differentiated corneal epithelial cells
RT-PCR analysis indicates that differentiated HCLE-NT cells express TLRs 2, 5, 6, and 10. 
An identical expression profile was observed in native corneal epithelial cells. In the figure, 
the panel labeled ‘Control’ included cDNA from a human monocytic cell line as template in 
the reactions. DNA molecular weight standards in kilobasepairs are indicated on the left of 
the gel.
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Figure 2. Distribution of TLR2 and TLR5 across the corneal epithelium
[A, B] Immunofluorescence microscopy on cross section of freshly obtained, non-cultured, 
human corneal epithelium using goat polyclonal anti-TLR2 antibody and mouse monoclonal 
anti-TLR5 antibody revealed that TLR2 and TLR5 are expressed by apical and subapical 
cells of the stratified corneal epithelium. In the (-) control condition, incubation was 
performed using the FITC-labeled secondary antibody in the absence of primary antibody. 
Nuclei are localized using DAPI. Scale bars=10 μm. [C, D] Western blots confirming that 
TLR2 and TLR5 are expressed on the surface of stratified HCLE-NT cells as determined by 
cell surface biotinylation (middle lanes labeled HCLE-NT cell surface). The lanes labeled 
HCLE-NT cell lysate and (+) Control contained 5 μg total protein. The (+) Control used was 
a lysate derived from undifferentiated THP-1 cells.
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Figure 3. Expression of proinflammatory cytokines in HCLE-NT, HCLE-scrMUC1, HCLE-
shMUC1, HCLE-scrMUC16, and HCLE-shMUC16 following exposure to TLR2 and TLR5 
agonists
[A, B] qRT-PCR analysis indicates that the message levels of the proinflammatory cytokines 
IL-6, IL-8, and TNF-α are increased in HCLE-shMUC1 and HCLE-shMUC16 cells in 
comparison to HCLE-NT, HCLE-scrMUC1, and HCLE-scrMUC16 cells following 
exposure of these cells to the TLR2 and TLR5 agonists, HKLM and flagellin, respectively. 
GAPDH was used as endogenous control in the qRT-PCRs. [C, D] Results from Luminex 
assays indicate that HCLE-shMUC1 and HCLE-shMUC16 cells secrete increased levels of 
IL-6, IL-8 and TNF-α following a 12 h exposure of the cells to HKLM and flagellin. Data 
shown are from experiments performed in biological triplicates. One way ANOVA was 
done to determine overall significance between groups. For internal comparisons, unpaired 
t-tests with Bonferroni correction were performed. *p<0.025 was considered significant.
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Figure 4. mRNA/protein expression and cell surface distribution of TLR2 and TLR5 in HCLE-
shMUC1 and HCLE-shMUC16 cells
[A] qRT-PCR and [B] immunoblot analyses demonstrate that the expression of TLR2 and 
TLR5 in HCLE-shMUC1 and HCLE-shMUC16 cells are not significantly different from 
HCLE-NT, HCLE-scrMUC1, and HCLE-scrMUC16 cells. Data shown in [A] are from 
experiments performed in biological triplicates. One way ANOVA was done to determine 
overall significance between groups. For internal comparisons, unpaired t-tests with 
Bonferroni correction were performed. p>0.025 was considered not significant (NS). In [B], 
whole cell extracts (5 μg) corresponding to HCLE-NT, HCLE-shMUC1, HCLE-scrMUC1, 
HCLE-scrMUC16, HCLE-shMUC16 cells were resolved by 12% SDS-polyacrylamide gel 
electrophoresis, followed by electroblotting and immunoblotting using TLR2 and TLR5-
specific antibodies. GAPDH served as the loading control. [C] Immunoblot showing that the 
apical distribution of TLR2 and TLR5 does not change between HCLE-NT, HCLE-
shMUC1, HCLE-scrMUC1, HCLE-scrMUC16, HCLE-shMUC16 cells as determined by 
cell surface biotinylation experiments. The lanes labeled (+) in [B] and [C] correspond to a 
lysate derived from undifferentiated THP-1 cells (5 μg).
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Figure 5. Expression of IL-6 and TNF-α in the corneal epithelium of Muc1-/- mice following 
exposure to a cocktail of TLR2 and TLR5 agonists
qRT-PCR analysis indicates that IL-6 and TNF-α message levels in the corneal epithelia of 
Muc1-/- mice (KO, gray, n=6) are elevated in comparison to WT mice (black, n=3) 
following exposure of enucleated eyes to a cocktail of the TLR2 and TLR5 agonists, HKLM 
and flagellin, respectively. Mouse GAPDH was used as endogenous control in the qRT-
PCRs. Unpaired t-tests with Welch correction were performed to determine significance. 
*p<0.05 was considered significant.
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Figure 6. Schematic of MUC1- and MUC16- mediated suppression of TLR signaling at the 
corneal epithelium
[A] MAMs form a glycocalyx on the apical membrane of the corneal epithelium. The 
micrograph shows an electron dense MAM glycocalyx (solid arrow) emanating from surface 
microplicae.58 [B] While the precise mechanisms by which MUC1 and MUC16 mediate 
suppression of TLR signaling at the corneal epithelium remain to be determined, both 
MAMs limit unnecessary TLR activation and expression of the proinflammatory cytokines 
IL-6, IL-8, and TNF-α. [C] Lack of MAMs results in increased TLR-induced expression of 
IL-6, IL-8, and TNF-α.
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